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immorally and deserved 
their infection. Eight 
percent felt that treating 
someone with HIV/AIDS 
was a waste of resources. 
Providers who reported 
working in facilities that 
did not always practice 
universal precautions 
against HIV transmission 
were more likely to favor 
restrictive policies towards 
PLWA. In general, basic 
materials needed for 
treatment and prevention 
of HIV infection were 
not sufﬁ  ciently available. 
Providers who reported 
less adequate training in HIV/AIDS 
treatment and in ethics were more likely 
to report negative attitudes towards 
patients with HIV/AIDS. There was no 
consistent pattern of differences in 
negative attitudes and practices across 
the different professions surveyed.
The researchers concluded that, while 
most health-care professionals surveyed 
reported being in compliance with 
their ethical obligations, discriminatory 
behavior and attitudes towards patients 
with HIV/AIDS existed among a signiﬁ  cant 
proportion. Inadequate education about 
HIV/AIDS and a lack of protective and 
treatment materials appear to favor these 
practices and attitudes. The ﬁ  ndings of 
the study, in just four states, cannot be 
generalized to Nigeria as a whole and, 
although sampled systematically, it is 
possible that sampled facilities and health-
care professionals may differ signiﬁ  cantly 
from those that were not sampled in the 
study states. Concerns over a perceived 
lack of privacy in the interviews or 
about job status may have resulted in 
an underreporting of discriminatory 
behavior and/or an overreporting of 
“correct” practices or attitudes. The 
authors note that the health-care system 
in Nigeria is underfunded and suffers 
from fundamental problems, including 
material scarcity and inadequacies 
in infrastructure, both of which may 
contribute to discriminatory behavior. 
They call for targeted education of 
health-care professionals and provision 
of adequate resources to health-care 
facilities, and for the introduction and 
enforcement of anti-discrimination 
policies.
Reis C, Amowitz LL, Heisler M, Moreland 
RS, Mafeni JO, et al. (2005) Discriminatory 
attitudes and practices by health workers 
toward patients with HIV/AIDS in Nigeria. 
DOI: 10.1371/journal.pmed.0020246
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People living with HIV/AIDS (PLWA) face 
many forms of stigma and discrimination. 
This is the case in whichever country they 
may live, as has been shown in a number 
of previous research studies. In addition 
to experiencing unfair treatment in their 
families, communities, and places of work, 
PLWA may encounter discrimination 
from health-care professionals. This can 
interfere with effective prevention and 
treatment. Discriminatory practices in the 
health-care sector may also appear to 
legitimize other forms of discrimination 
against PLWA. 
Vincent Iacopino and colleagues from 
the organization Physicians for Human 
Rights, in collaboration with researchers 
from Policy Project–Nigeria and the Center 
for the Right to Health (also in Nigeria) 
investigated the problem in Nigeria. With a 
population of roughly 130 million, Nigeria 
is home to one in 11 of the 40 million 
PLWA worldwide. Around 6% of adult 
Nigerians are thought to be HIV-positive, 
and there will be an estimated 310,000 
AIDS deaths this year. The indications are 
that infection rates will increase. Until now, 
little has been known about the nature 
and extent of discrimination against 
patients with HIV/AIDS in Nigeria.
Trained interviewers conducted a 
cross-sectional questionnaire survey of 
1,021 Nigerian health-care professionals 
in 111 health-care facilities in four of 
Nigeria’s 36 states. Those sampled were 
324 physicians, 541 nurses, and 133 
midwives, and 23 health-care workers of 
unknown profession. Fifty-four percent 
of them worked in public tertiary 
care facilities. Many of the survey’s 
results are worrying. Nine percent of 
professionals reported refusing to care 
for a patient with HIV/AIDS, and 9% said 
they had refused a patient with HIV/
AIDS admission to a hospital. Fifty-nine 
percent agreed that PLWA should be 
on a separate ward, and 40% believed a 
person’s HIV status could be determined 
by their appearance. Ninety-one percent 
agreed that staff should be informed 
when a patient was HIV-positive in order 
to protect themselves. Forty percent 
believed health-care professionals with 
HIV/AIDS should not be allowed to work 
in any area of health-care requiring 
patient contact. Twenty percent agreed 
that many with HIV/AIDS had behaved 
How Do Nigeria’s Health-Care Personnel Treat Patients with HIV/AIDS?
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Training of interviewers for the study included 5 days of 
classroom teaching and role-playing
The World Health Organization 
estimates that about 20% of all deaths 
in children younger than ﬁ  ve years old 
are due to acute lower respiratory tract 
infections (LRTIs), with 90% of these 
deaths due to pneumonia. But despite 
LRTIs being among the most frequent 
diseases in the ﬁ  rst years of life, the viral 
causes of these illnesses are not always 
clear. Several viruses are known to be 
involved, e.g., respiratory syncytial virus 
(RSV), inﬂ  uenza viruses, parainﬂ  uenza 
viruses, and human metapneumovirus, 
but none of these pathogens is detected 
in a substantial number of cases.
In a new article published in PLoS 
Medicine, Lia van der Hoek and colleagues 
investigate the association of acute LRTIs 
with human coronavirus HCoV-NL63, 
a virus they recently described. They 
suggest that HCoV-NL63, a new member 
of the Coronaviridae family, is one of 
the most frequently detected viruses 
in children less than three years old 
with LRTIs and that this virus is strongly 
associated with croup.
A Novel Virus for Croup 
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The team analyzed samples from the 
PRI.DE study, a prospective population-
based study of LRTIs in children younger 
than three years old in Germany. 
They assessed by PCR 949 samples 
of nasopharyngeal secretions from 
children with LRTIs. 
In all, 49 samples (5.2%) were positive 
for HCoV-NL63 RNA. Viral RNA was more 
prevalent in samples from outpatients 
(7.9%) than hospitalized patients (3.2%), 
and co-infection with either RSV or 
parainﬂ  uenza virus 3 was observed 
frequently. With an overall occurrence 
of 5.2%, HCoV-NL63 was the third 
most frequently detected pathogen 
in this patient group (RSV was the 
highest, found in 31.4% of samples). The 
researchers focused on HCoV-NL63 in 
cases of respiratory disease where no 
other viral pathogen could be detected 
in order to identify clinical symptoms 
associated with HCoV-NL63 infection. 
Samples in which only HCoV-NL63 RNA 
could be detected had a signiﬁ  cantly 
higher viral load than samples containing 
additional respiratory viruses. A strong 
association with croup was apparent: 
43% of the HCoV-NL63-positive patients 
with high HCoV-NL63 load and absence 
of co-infection had croup, compared 
with 6% in the HCoV-NL63-negative 
group. Indeed, a signiﬁ  cantly higher 
fraction (17.4%) of samples from croup 
patients than non-croup patients (4.2%) 
contained HCoV-NL63 RNA.
This study strengthens the evidence for 
the role of HCoV-NL63 in croup. Previous 
studies have shown croup to occur 
mostly in boys, with peak occurrence in 
the second year of life and predominantly 
in the late autumn or early winter season. 
And HCoV-NL63 infection seems to follow 
these trends, said the authors.
However, the authors warned that the 
high percentage of HCoV-NL63-positive 
samples could be due to a strong viral 
activity in the study year, and long-term 
studies are needed to determine whether 
HCoV-NL63 infections occur in cycles 
peaking every two to three years, as 
observed for other respiratory viruses. 
But they noted that HCoV-NL63 has 
spread worldwide, with the virus found 
in Australia, Canada, Japan, Belgium, and 
the US. Thus, health authorities should 
add HCoV-NL63 to the list of pathogens 
that can cause numerous LRTIs in young 
children.
van der Hoek L, Sure K, Ihorst G, Stang A, 
Pyrc K, et al. (2005) Croup is associated with 
the novel coronavirus NL63. DOI: 10.1371/
journal.pmed.0020240
Approximately 40% of the world’s 
population, mostly living in the world’s 
poorest countries, is at risk of malaria. 
In the tropical and subtropical regions 
of the world, malaria causes 300 million 
acute illnesses and at least 1 million 
deaths annually. Ninety percent of these 
deaths occur in Africa, south of the 
Sahara, mostly among young children.
To assess disease severity, peripheral 
blood parasitemia is measured, but this 
is only a weak predictor of mortality 
in falciparum malaria. In addition, a 
microscopist is only able to count the 
less pathogenic circulating stages of the 
parasite, whereas the more pathogenic 
parasitized erythrocytes, sequestered in 
the capillaries and containing mature 
parasites, are not seen and therefore 
not counted. However, sequestered 
Plasmodium falciparum parasites secrete 
Histidine-rich protein 2 (PfHRP2), which 
is liberated into the plasma at schizont 
rupture.
In this month’s PLoS Medicine,
Arjen Dondorp and colleagues suggest 
that the plasma concentration of this 
protein might provide a better estimate 
for the patient’s total parasite biomass 
and therefore be a more accurate 
prognostic indicator than circulating 
parasite load. There is evidence to 
support this hypothesis. A recent study 
by the same team measured PfHRP2 
in P. falciparum cultures, and showed 
that approximately 89% of PfHRP2 is 
liberated at schizont rupture and that 
the variation in the amount released 
is limited.
In the current study the researchers 
measured plasma PfHRP2 concentrations 
in 337 patients with varying severity 
of falciparum malaria and, using a 
simple mathematical model, estimated 
the total body parasite biomass. This 
value was compared with measures 
of disease severity and outcome. The 
developmental stage distribution of 
circulating parasites, which also provides 
information on the sequestered parasites, 
was also evaluated in relation to plasma 
PfHRP2 levels in these patients.
The researchers found that the 
estimated geometric mean parasite 
burden was more than six times higher 
in patients with severe malaria than in 
patients hospitalized without signs of 
severe disease, and was highest in patients 
who died. Statistical analysis revealed that 
the estimated total parasite biomass was 
clearly associated with disease severity 
and outcome. By contrast, peripheral 
blood parasitemia and the number of 
circulating parasites were not associated 
with disease outcome, nor with other 
measures of severity such as admission 
plasma lactate concentrations.
The ﬁ  nding that sequestered parasite 
biomass is associated with disease 
severity ﬁ  ts with current thinking that 
sequestration of erythrocytes containing 
the mature forms of the parasite is the 
central pathological process in falciparum 
malaria.
However, the team noted there were 
several factors that might contribute 
to inaccuracies in the model. For 
example, the amount of PfHRP2 
secreted per parasite varies between 
different parasite strains. Also, in high 
transmission areas, where partial 
immunity against the disease develops, 
Measuring Hidden Parasites in Falciparum Malaria
DOI: 10.1371/journal.pmed.0020268
DOI: 10.1371/journal.pmed.0020268.g001
Stages in the life cycle of Plasmodium
falciparum
(Illustration: Coatney GR, Collins WE, Warren 
M, Contacos PG (1971)
The primate malarias. (Bethesda): U.S. 
Department of Health, Education and 
Welfare.)
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Animal models can play an essential 
role in guiding preclinical vaccine 
development, including in studies 
of preclinical vaccine safety, vaccine 
toxicity, and vaccine immunogenicity. 
Appropriate pathogen challenge models 
can also provide the opportunity to 
perform preclinical tests of vaccine 
efﬁ  cacy. Preclinical tests of HIV 
vaccine efﬁ  cacy are usually performed 
by exposing macaques to simian 
immunodeﬁ  ciency virus (SIV), a virus 
that is closely related to HIV. However, 
the viral inoculum sizes used to infect 
macaques with SIV vastly exceed 
the amounts of HIV that humans are 
exposed to during a given exposure. 
Typically animals are exposed to 10–100 
times the infectious dose at which 50% 
of the animals become infected (ID50). 
These excessive doses may not provide 
realistic preclinical tests of vaccine 
efﬁ  cacy. Indeed, no vaccine has been 
shown to be effective in preventing 
infection by SIV (so-called sterilizing 
immunity) in such high viral inoculum 
trials. Now, in a paper published in PLoS 
Medicine, Roland Regoes and colleagues 
speculate that an alternative approach 
to trials in animals not only can mimic 
the human patterns of repeated low-
dose exposure, but also can remove one 
concern for animal researchers—the 
need to use very large numbers of 
animals in experiments.
What the researchers did was use 
statistical power analysis to compare 
a single low-dose challenge design, 
in which each animal is challenged 
only once, and a repeated low-dose 
challenge design, in which each animal 
is challenged until it is infected or a 
predetermined maximum number of 
challenges is reached. The statistical 
power of an experimental design—a 
measure of the statistical quality—was 
assessed by simulating experiments, 
evaluating them, and then repeating the 
procedure thousands of times. 
What they found was that the 
experimental design using a single low 
dose of virus in each animal required 
unfeasibly large numbers of animals; 
even for the highest modeled vaccine 
efﬁ  cacy of 90% the single low-dose 
challenge design required more than 20 
animals per group to reach a statistical 
power of 95%. However, when the 
researchers modeled a protocol of 
repeatedly challenging the (virtual) 
animals with a challenge dose of one ID50,
and allowing for a maximum number of 
20 challenges of each individual animal, 
as few as ﬁ  ve animals were required to 
achieve more than 95% of statistical 
power. 
Where do these results leave the 
design of HIV trials? To begin with, the 
results should encourage researchers 
to develop animal models that reﬂ  ect, 
to the fullest extent possible, what 
is known about the natural history 
and pathogenesis of the disease in 
humans, rather than designing trials to 
ﬁ  t the animal models that are available. 
The authors have made available the 
programming script of their analysis 
so anyone can repeat it; it would be 
interesting to know whether preclinical 
trials assessing vaccines or treatments 
against infections by other pathogens 
could be usefully modeled in this way as 
well.
Regoes RR, Longini IM Jr, Feinberg MB, 
Staprans SI (2005) Preclinical assessment of 
HIV vaccines and microbicides by repeated 
low-dose virus challenges. DOI: 10.1371/
journal.pmed.0020249
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clearance of PfHRP2 might be increased 
in the presence of antibodies against 
the protein; in these areas—such as 
countries in sub-Saharan Africa—the 
model would thus underestimate the 
parasite burden and might need to be 
adapted further for use.
Despite these issues, estimates of 
plasma PfHRP2 concentrations may 
be useful as a research tool to stratify 
patients’ parasite loads, say the authors. 
They conclude that quantitative 
measurements of plasma PfHRP2 in 
patients with falciparum malaria could 
be used to estimate the total parasite 
biomass, a parameter pivotal in the 
pathophysiology of the disease, and that 
this total parasite biomass is associated 
with clinical measures of the severity of 
the disease.
Dondorp AM, Desakorn V, Pongtavornpinyo 
W, Sahassananda D, Silamut K, et al. 
(2005) Estimation of the total parasite 
biomass in acute falciparum malaria from 
plasma PfHRP2. DOI: 10.1371/journal.
pmed.0020204
Inﬂ  ammatory bowel disease (IBD) 
is the term that encompasses chronic 
relapsing diseases characterized by 
inﬂ  ammation of the bowel, speciﬁ  cally 
ulcerative colitis (UC) and Crohn disease 
(CD). They are common disorders; in 
the UK, for example, together they 
affect about one person in every 400, 
amounting to a total of 120,000 cases 
of UC and 60,000 of CD, with 6,000 new 
cases of UC and 3,000 new cases of 
CD every year. Current estimates total 
at more than 1 million cases in the US 
and Europe. The symptoms for both 
these conditions—which suggest an 
abnormal immune response at the 
intestinal mucosa—include abdominal 
pain, diarrhea, fever, severe fatigue, and 
weight loss. Current understanding of 
disease pathogenesis suggests a complex 
action of multiple environmental factors 
that trigger disease in individuals with a 
susceptible genetic background.
Today, ﬁ  nding genes that have a 
role in diseases has been made easier 
by the sequencing of the human 
genome and creation of an expressed 
sequence tag clone database. Previous 
positional cloning studies have revealed 
three genes associated with IBD that 
carry variants with a causative role. 
Another of the tools for analyzing 
genes is microarray technology, in 
which the expression of transcripts of 
thousands of genes can be investigated 
simultaneously. This approach offers an 
insight into disease pathophysiology. 
In a research article published in 
PLoS Medicine, Christine Costello and 
colleagues have gone further with cDNA 
microarrays to attempt to decipher 
gene regulatory events and identify 
genes that might be involved in the 
pathophysiology of these IBD. They 
found 650 genes that were differentially 
regulated between normal control 
individuals and the individuals with one 
of the two IBD subtypes. In fact, 500 and 
272 differentially regulated transcripts 
were identiﬁ  ed between control 
individuals and patients with CD and 
UC, respectively. There was an imbalance 
between over- and underexpressed 
genes in the IBD subtypes. In CD, 
approximately 84% of differentially 
expressed genes were found to be down-
Dissecting Out Differences 
in the Transcriptomes of 
Inﬂ  ammatory Bowel Disease
DOI: 10.1371/journal.pmed.0020273
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regulated compared with 42% of genes 
in UC. However, the authors caution that 
this ﬁ  nding was highly inﬂ  uenced by the 
types and numbers of genes present on 
any microarray system; in addition, none 
of the 122 differentially expressed genes 
in CD and UC was overexpressed in one 
disease and underexpressed in the other. 
These observations support the notion 
of a shared general inﬂ  ammatory proﬁ  le 
underlying each form of IBD, with more 
speciﬁ  c events in the pathophysiological 
cascade being disease-speciﬁ  c. 
In a second part of the study, the 
team tried to interpret the functional 
consequences of changes in gene 
expression observed in the microarray 
analysis. They used an annotation-based 
pathway database, which classiﬁ  ed 
differentially expressed genes into 
three major groups: immune and 
inﬂ  ammatory response; oncogenesis, 
cell proliferation, and growth; or 
structure and permeability. For immune 
and inﬂ  ammatory response, the team 
identiﬁ  ed many genes associated with 
aberrant immune response; it is not 
surprising, perhaps, to ﬁ  nd a general 
up-regulation of immune response and 
antigen presentation in IBD. Several 
genes associated with cell growth and 
proliferation were up-regulated in UC—a 
ﬁ  nding similar to previous microarray 
studies that had reported involvement of 
cancer-related genes in IBD (although the 
altered genes were different). There was 
also an enrichment of genes associated 
with structure and permeability; in this 
class several genes were ubiquitously 
altered in both IBD and non-IBD samples, 
reﬂ  ecting dysregulation of genes for 
paracellular permeability, degradation 
of extracellular matrix, and barrier 
protection against bacterial invasion of 
the epithelial surface.
Ultimately this study highlights the 
complex pathogenesis of UC and CD, and 
indicates some possible future avenues 
for research of mucosal diseases in 
general. It demonstrates that genomic 
technologies are suitable to directly 
dissect human pathophysiology.
Costello CM, Mah N, Häsler R, Rosenstiel P, 
Waetzig GH, et al. (2005) Dissection of the 
inﬂ  ammatory bowel disease transcrptome 
using genome-wide cDNA microarrays. 
DOI: 10.1371/journal.pmed.0020199
DOI: 10.1371/journal.pmed.0020273.g001
Colonoscopy images of normal control, 
Crohn Disease (CD) and ulcerative 
colitis (UC) patients (top, left to right). 
Differentially expressed genes in controls 
vs. CD (lower left) and controls vs. UC 
patients (lower right).
Dementia remains an incurable condition and its increasing 
prevalence is a deeply worrying aspect of the “graying” of 
the population. An important question for researchers is to 
establish whether dementia incidence, prevalence, and national 
history vary from one location to another. Incidence studies 
are particularly valuable for less biased comparison of disease 
occurrence, as well as being essential for policy makers. Many 
biases can, however, be introduced in such studies. Dropout and 
mortality are particular reasons for concern.
Most of the numerous studies of dementia incidence 
have been restricted to single sites. Authors have frequently 
attempted to assess whether rates in a given study are similar 
to those obtained elsewhere. However, variations between 
studies in the methodology employed make such comparisons 
unreliable. Where within-country variations in incidence have 
been noted, as has happened in the US, they have often been 
ascribed to methodological differences, but one cannot be 
certain whether this is the case. 
Risk factors for other chronic disorders common in old age 
(notably cardiovascular disease and cancers) do vary in their 
prevalence between and within countries. In the UK, for example, 
the incidence of stroke is known to vary considerably across the 
country. A high proportion of dementia patients are thought to 
have a vascular component to their dementia, and it has been 
assumed that dementia incidence could be reduced if vascular 
risk were better controlled. One way to test this hypothesis is 
to compare sites with known variation in vascular risk to assess 
whether there is also variation in the incidence of dementia.
The Medical Research Council Cognitive Function and Ageing 
Study (MRC CFAS) is a multi-site, population-based study in the 
UK of individuals aged 65 years and over living in the community, 
including institutions. Diverse sites have been chosen, with 
varying exposures of potential importance in dementia. A two-
phase two-wave design has been employed, with the waves 
two years apart. A standard set of instruments for the diagnosis 
of dementia is used throughout. CFAS now publishes incidence 
estimates from ﬁ  ve sites, using likelihood-based methods to 
compare the ﬁ  rst two waves of interviews. 
Predictably, incidence rates of dementia, for both sexes, were 
found to rise with age, from 6.7 per 1,000 person years at age 
65–69 years to 68.5 per 1,000 person years at age 85 years and 
above. The authors estimate that around 163,000 new cases of 
dementia occur in England and Wales each year. However, there 
was no convincing evidence of variation across sites, and the 
incidence rates do not reﬂ  ect the variations in the prevalence of 
possible risk factors in these sites. We therefore cannot assume 
that action to reduce vascular risk will have a signiﬁ  cant impact 
on dementia incidence.
Another issue addressed by the study is previous suggestions 
in the literature that dementia incidence rates might be lower 
in the oldest age groups. The limited number of respondents 
in these age groups in previous studies made it impossible to 
test this hypothesis. The CFAS, however, found no evidence of 
any such tailing off in incidence, which also has implications for 
policy and planning. 
The CFAS is important because it provides the ﬁ  rst multi-
site comparison of incidence rates in ethnically homogeneous 
populations within a country, and within Europe, using identical 
methodology across sites. The methodological approach 
developed for the study will also be of value for researchers 
undertaking other studies of dementia incidence, and in other 
chronic disease studies involving a two-phase selection process.
Brayne C, Matthews F, Medical Research Council Cognitive Function 
and Ageing Study Investigators (2005) The incidence of dementia in 
England and Wales: Findings from the ﬁ  ve identical sites of the MRC 
CFA study. DOI: 10.1371/journal.pmed.0020193
UK Dementia Incidence Doesn’t Vary across Sites with Known Variation in Vascular Risk
DOI: 10.1371/journal.pmed.0020275
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